Gary Schiller

Gary Schiller, MD, FACP

Professor, Department of Medicine, Hematology/Oncology
Director, Hematological Malignancies/Stem Cell Transplantation Unit


English, Spanish, Hebrew, German


Hematologic Oncology, Hematology

Institutional Affiliation

Ronald Reagan UCLA Medical Center



Medicine, Hematology/Oncology, UCLA School of Medicine, 1987 - 1990


Internal Medicine, UCLA School of Medicine, 1984 - 1985


MD, USC School of Medicine, 1984


Internal Medicine, UCLA School of Medicine, 1985 - 1987

Board Certifications

Hematology, American Board of Internal Medicine, 1990
Medical Oncology, American Board of Internal Medicine, 1989
Internal Medicine, American Board of Internal Medicine, 1987

Contact Information


(310) 206-6909 - Hematology/Oncology information and patient appointments
(310) 206-6931 - UCLA Oncology Center information and patient appointments
(310) 794-7177 - Therapeutic Hemapheresis information and referral
(310) 825-4968 - Transfusion Medicine information and referral

Clinical Interests

Acute Myeloid Leukemia, Bone Marrow Transplantation, Chronic Myelogenous Leukemia, General Hematology, Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplasia, Stem Cell Transplant

Scientific Interests

Dr. Gary Schiller's research projects include: clinical studies of new drugs, therapies and bone marrow transplantation for patients with malignancies of the blood or bone marrow such as leukemia, multiple myeloma and lymphoma.

Schiller has carried out studies of stem cell transplantation following high-dose chemotherapy and radiation for acute myelogenous leukemia, one of the most common types of leukemia in adults. Schiller has also carried out work with purified stem cell transplantation for multiple myeloma. He and his colleagues are conducting ongoing studies using new drugs and therapeutics for chronic lymphocytic leukemia, chronic myelogenous leukemia and multiple myeloma. The researchers are also studying certain kinds of non-Hodgkin's lymphoma. Schiller's approach is to put into clinical trials new treatments developed in the laboratory for patients with blood stem cell diseases or cancers of the bone marrow and blood.

Highlighted Publications

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Rollig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.

Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Erratum in: Lancet Oncol. 2015 Apr;16(4):e158.

Sasine JP, Schiller GJ. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Blood Rev. 2015 Jan;29(1):1-9. doi: 10.1016/j.blre.2014.07.002. Epub 2014 Jul 16. Review.

Schiller GJ. Evolving treatment strategies in patients with high-risk acute myeloid leukemia. Leuk Lymphoma. 2014 Nov;55(11):2438-48. doi: 10.3109/10428194.2014.881479. Epub 2014 Mar 7. Review.

Schiller GJ. High-risk acute myelogenous leukemia: treatment today ... and tomorrow. Hematology Am Soc Hematol Educ Program. 2013;2013:201-8. doi: 10.1182/asheducation-2013.1.201. Review.